Studies conducted at MTR were approved by various regulatory bodies such as
US FDA,
TPD-Canada,
EMEA,
ANSM-France,
ANVISA-Brazil,
Bfarm-German,
TGA-Australia,
MCC-South Africa,
Russia,
Belgium,
Philippines,
WHO, etc.
MTR has successfully exceeded the dual audit
of Bfarm (German) and ANSM (France)
in March 2013, Market Authorization has
granted for audited molecule.
All three facilities {Selaiyur, Padi & Coimbatore)
of MTR are registered with FDA
for “self identified”, as per
Generic Drug User Fee Amendments of 2012 (GDUFA)
-FDA for fiscal year 2014.
MTR has successfully completed US-FDA audit
in Dec 2012 with NIL 483.
MTR Chennai & CBE facilities were approved
by ANVISA (Brazil).
MTR is shortlisted among
“5 Best Contract Research Organization”
in the year 2012, by Scrip Intelligence Awards.
MTR has obtained reorganization from DSIR
as “RESEARCH CENTER” in the month of July 2012.
Forthcoming –
On 15 Feb 2014, MTR will successfully
complete its 9th year of operation.
In 2014-MTR will provide extensive services
in the field of Preclinical trial, Biosimilar, Stem cell.
MTR has applied for registration of its
bioequivalence (BE) centre to Centre of New
products, NPCB, ministry of health Malaysia.
US FDA,
TPD-Canada,
EMEA,
ANSM-France,
ANVISA-Brazil,
Bfarm-German,
TGA-Australia,
MCC-South Africa,
Russia,
Belgium,
Philippines,
WHO, etc.
MTR has successfully exceeded the dual audit
of Bfarm (German) and ANSM (France)
in March 2013, Market Authorization has
granted for audited molecule.
All three facilities {Selaiyur, Padi & Coimbatore)
of MTR are registered with FDA
for “self identified”, as per
Generic Drug User Fee Amendments of 2012 (GDUFA)
-FDA for fiscal year 2014.
MTR has successfully completed US-FDA audit
in Dec 2012 with NIL 483.
MTR Chennai & CBE facilities were approved
by ANVISA (Brazil).
MTR is shortlisted among
“5 Best Contract Research Organization”
in the year 2012, by Scrip Intelligence Awards.
MTR has obtained reorganization from DSIR
as “RESEARCH CENTER” in the month of July 2012.
Forthcoming –
On 15 Feb 2014, MTR will successfully
complete its 9th year of operation.
In 2014-MTR will provide extensive services
in the field of Preclinical trial, Biosimilar, Stem cell.
MTR has applied for registration of its
bioequivalence (BE) centre to Centre of New
products, NPCB, ministry of health Malaysia.
Welcome...
Micro Therapeutic Research Labs Private Limited (MTR) is a quality driven, full service Clinical Research Organization (CRO) that provides a broad range of clinical research services to global Pharmaceutical, biotechnology, nutraceutical and cosmetic industry.
Spreaded over three different locations namely Tambaram & Padi at Chennai and Coimbatore , Tamilnadu at southern part of India.A State with rich cultural heritage.
Regulatory Status and Accreditation
